Meda: Nothing to sneeze at

[at Financial Times] – Bless you! Investors in Meda might have said on Friday. News of an (albeit rejected) approach to the Swedish pharma company, which specialises in allergy remedies, by US generic drugmaker Mylan sparked … more

View todays social media effects on MYL

View the latest stocks trending across Twitter. Click to view dashboard

See who Mylan is hiring next, click here to view